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Abstract 
Background 
People who inject image & performance enhancing drugs (IPEDs) are often the largest 
group using needle and syringe programmes (NSPs) in the UK. NSP providers report these 
clients repeatedly collecting large amounts of equipment for others. The extent of secondary 
distribution of injecting equipment is unknown. 
Methods 
Data from national surveillance of people injecting IPEDs was used. Participants completed 
a questionnaire and provided a dried-blood spot sample. Data from two biennial surveys was 
combined; repeat participants were excluded. Self-reported data was used to explore the 
extent of secondary distribution. 
Results 
Of the participants 87% (467) reported NSP use: median age 31 years, 98% male. A third 
(34%, 157) reported collecting equipment for others. Of those collecting for others, 154 
reported how many people they had collected for: 55% had collected for one person, 27% 
for 2-9 people, 5% for 10-19 and 13% for 20 or more (no difference by psychoactive drug 
use). Those vaccinated for hepatitis B were more likely (22% [15/68] vs 6% [5/86], p=0.003) 
and those reporting redness/swelling at an injection site were less likely to collect equipment 
for at least 20 others (8% [8/106] vs 25% [12/48], p=0.003). Overall, 154 people collected 
equipment for 639-1,569 people injecting IPEDs. 
Conclusions 
Secondary distribution of injecting equipment is common among those injecting IPEDs and 
using NSPs. Whilst not allowing for rotational collection within groups, our analysis suggests 
that many of those injecting IPEDs are not in direct contact with NSPs. Innovation 
approaches for harm reduction interventions are needed. 
Word count: 249/250 
  
1. Introduction 
Historically, the use of IPEDs, such as anabolic steroids, had predominately been for athletic 
purposes (Begley et al., 2017). In recent years the range of drugs and prevalence of use for 
both aesthetic and athletic purposes has increased in England and Wales (Bates et al., 
2014; Begley et al., 2017; Home Office, 2016). UK needle and syringe programmes (NSP) 
often report seeing more people who inject IPEDs than people who inject psychoactive 
drugs (Bates et al., 2014; McVeigh and Begley, 2017). Increased NSP use by those injecting 
IPEDs has been reported in other high income countries, with international debate 
concerning adequate service provision (Iversen et al., 2016). 
Appropriate harm reduction interventions are vital to prevent adverse health outcomes, 
including blood borne viral (BBV) and skin and soft tissue infections (SSTI); 1 in 20 people 
who inject IPEDs in the UK are hepatitis C antibody positive and 1 in 7 report SSTI 
symptoms (Hope et al., 2013; Public Health England, July 2015). UK policy is to provide free 
needles and syringes to all people who inject drugs (PWID) and to support the return of used 
equipment (NICE, 2014b). The IPED injecting population is receptive to NSPs (NICE, 
2014b). However, due to the cyclical nature of IPED use (Chandler and J.McVeigh, 2013), 
involving planned periods of use and non-use, NSP attendance among people using IPEDs 
can be less frequent and more seasonal compared to those injecting psychoactive drugs, 
with IPED injectors often collecting large quantities of equipment (McVeigh et al., 2003).  
Qualitative research indicates secondary distribution is occurring, where people who inject 
IPEDs collect injecting equipment for distribution through their peer networks (McVeigh et 
al., 2007). UK guidance recommends that services should not discourage secondary 
distribution, but should encourage its recipients to personally attend NSPs for harm 
reduction interventions (NICE, 2014b). Among people who inject psychoactive drugs, 
secondary distribution is evident (Craine et al., 2010; De et al., 2008; Lorvick et al., 2006), 
with those reporting this as their primary source of clean equipment being younger and less 
experienced, and so probably more vulnerable, PWID (Craine et al., 2010). The extent of 
peer-distribution within IPED networks is unclear, but could be considerable with the 
recipients potentially being a vulnerable population not reached by current interventions.  
We estimate the current extent and nature of the secondary distribution of injecting 
equipment from English and Welsh NSP by people injecting IPEDs.  
2. Methodology 
Data from a national cross-sectional survey was used.  As part of the Unlinked Anonymous 
Monitoring (UAM) Survey of PWID a biennial sub-survey of people injecting IPEDs was 
undertaken. Methodological details have been previously reported (Hope et al., 2013). In 
summary, people who have ever injected IPEDs were recruited through sentinel 
collaborating NSPs or outreach services. Participants completed a questionnaire and 
provided a dried blood spot sample, which was tested for antibodies against HIV, hepatitis B 
and hepatitis C (Hope et al., 2016; Hope et al., 2017).The survey has multi-site ethical 
approval from NHS Health Research Authority (MREC/98/2/51). 
Data from two survey waves, covering the period 2012-2015 from 29 sentinel services were 
used. Participants in the second wave who reported participating in the first wave were 
excluded. Exploratory analysis found missing data in binary variables did not differ in the 
outcome variable to the non-affirmative responses, so missing data were recoded as such.  
Descriptive and comparative analyses were conducted, using Pearson’s Chi-squared test, to 
examine bivariate associations (p<0.05) between the outcome variable (collecting equipment 
for others) with covariates (demographics, injecting practices, intervention uptake and BBV 
status).  
Participants reporting NSP use were asked whether they had collected injecting equipment 
for others, and how many additional people they routinely collected for, categorised as: 1, 2-
9, 10-19 and 20+ others. To assess the extent of onward distribution sensitivity analysis was 
conducted, producing a minimum, mid-point and maximum estimate. Bivariate associations 
were examined for those reporting extensive onward distribution (to ≥20 others) and those 
who have ever injected IPEDs and psychoactive substances, with covariates previously 
described. Analyses were conducted in STATA 13. 
3. Results 
Of the 537 participants, 467 (87%) reported NSP use (Table 1). The demographic 
characteristics and injecting practises of those using NSP and those not were similar; 
reporting of redness or swelling at an injection site was, however, higher among the NSP 
users (Table 1). The median age of those reporting NSP use was 31 years, 98% were men, 
1.5% (n=7) were living with HIV, 3.0% (n=14) and 5.1% (n=24) had ever had hepatitis B and 
hepatitis C respectively. 
The IPEDs injected were those commonly reported, with 98% reporting use of anabolic 
steroids. One-third (34%, n=157) of those using NSPs reported usually collecting injecting 
equipment for others; the median age at first NSP use for those collecting for others was 26 
years and their median time since first NSP use was five years (N=123).  
Those collecting injecting equipment for others were more likely to report ever having 
redness, tenderness and swelling (68% vs 58%, p=0.029) and SSTI symptoms (21% vs 
13%, p=0.029) at an injection site than those not collecting equipment for others (Table 1). 
Additionally, those reporting secondary distribution were more likely to also inject 
psychoactive substances (ever: 19% vs 11%, p=0.021; recently: 11% vs 4%, p=0.011) and 
report ever sharing a drugs vial (18% vs 9%, p=0.002) (Table 1). There was no difference in 
age. 
3.1 Use of psychoactive drugs 
Injecting psychoactive drugs in the past year was rare. Overall, 8% (n=36) of participants 
reported ever injecting heroin, 8% (n=36) cocaine, and 7% (n=32) speed. Participants who 
had ever injected IPEDs and who also reported injecting psychoactive drugs during the past 
year (6%, n=29) were older, (median age 38 vs 30 years, p=0.0013) than those only 
injecting IPEDs (n=438), and more likely to have ever been incarcerated (69% [20/29] vs 
22% [96/438], p<0.001), vaccinated for hepatitis B (83% [24/29] vs 38% [166/438], p<0.001), 
ever tested for hepatitis C (83% [24/29] vs 36% [157/438], p<0.001), reported symptoms of 
an SSTI (38% [11/29] vs 14% [63/438], p=0.001) and re-used injecting equipment (79% 
[23/29] vs 13% [55/438], p<0.001). 
3.2 Extent of secondary distribution 
Of the 154 who reported the number of other people they collected for, over half (55%) 
usually collected for one other person, around a quarter (27%) collected for two to nine other 
people, and 5% collected for ten to nineteen other people. The remaining 13% (4% of the 
overall sample) reported usually collecting for twenty or more other people (Table 2). 
Overall, 154 people collected equipment for at least another 639 people injecting IPEDs. A 
less conservative approach, using a mid-point estimate, suggests collection for an additional 
1,000 people injecting IPEDs, and at most an additional 1,569 people were collected for 
(Table 2). 
Considering extensive onward distribution, those vaccinated for hepatitis B were more likely 
to collect equipment for at least 20 others (22% [15/68] vs 6% [5/86], p=0.003) and those 
ever reporting redness or swelling at an injection site were less likely to collect equipment for 
at least 20 others (8% [8/106] vs 25% [12/48], p=0.003). There were no significant 
differences with age, gender, BBV infection or the injection of psychoactive drugs.  
Among those reporting secondary distribution there was no difference in the number of 
people they collected for, between those who had and those who had not injected 
psychoactive drugs in the preceding year (p=0.456). 
  
4. Discussion 
Our analysis confirms anecdotal reports that secondary distribution of injecting equipment 
obtained from NSPs by people who inject IPEDs is common, aligning with the single 
previous UK study (McVeigh et al., 2003). Moreover, our conservative estimate found more 
people received equipment indirectly through secondary distribution than directly from an 
NSP and, at most, the population indirectly supplied was around three times the size of our 
sample.  
Although the extent of secondary distribution estimated has a wide range, it suggests that 
the group of people using IPEDs and not in direct contact with NSPs is probably large. 
Secondary distribution enables widespread needle delivery, allowing connection with hard to 
reach users (Kimergård and McVeigh, 2014) and is more effective in reducing BBV 
transmission than restrictive policies (Kerr et al., 2010). However, those obtaining injecting 
advice exclusively from peers could mimic their peer’s behaviours. If so, our finding that 
collecting for others was associated with sharing equipment and SSTI symptoms is a 
concern. The HIV prevalence among those injecting IPEDs and accessing NSPs than in the 
general UK population is higher (Kirwan et al., 2016). Although prevalence among recipients 
of onward equipment distribution is unknown, those not in NSP contact may be at greater 
risk (Public Health England et al., 2016). Our findings, therefore, highlight the importance of 
alternative platforms and improved approaches for delivering harm reduction interventions to 
people injecting IPEDs.  
One approach would be to utilise the secondary distribution process by engaging those 
collecting as peer educators (Bates et al., 2014; Marshall et al., 2015).  This has previously 
been shown to be effective among people using psychoactive drugs (Anderson et al., 2003; 
Broadhead et al., 1998; Craine et al., 2006; Grund et al., 1992; Winyard, 2005), with 
distributors displaying a health-related altruism to protect others from harm (Bryant and 
Hopwood, 2009; Snead et al., 2003). Among people using IPEDs, knowledge around IPED 
use is sourced primarily from peers, despite their knowledge sometimes being incomplete or 
inaccurate (Hanley Santos and Coomber, 2017).  
Secondly, using social media and online networking for health promotion should be 
considered (Gold et al., 2012). Currently, people using IPEDs often rely on online forums 
and websites for information, which can be misleading or inaccurate and thus leading to 
harms (Bates et al., 2014).  As IPEDs and injecting equipment are often sourced online 
(Andreas et al., 2014; Kimergard and McVeigh, 2014), NSPs could offer online ordering of 
injecting equipment, incorporating education to improve injecting practices, to engage with 
this group. 
Thirdly, innovative outreach approaches within the IPED community could offer unique 
access, for delivery of both education and NSPs. The participants who reported extensive 
secondary distribution may have been collecting for specific gyms. They reported higher 
uptake of interventions and lower levels of poor injecting practices, indicative of an 
experienced sub-group with safer behaviours, thus potentially suitable candidates for 
delivering peer-led gym-based programmes. Such programmes do exist (NICE, 2014a) 
including informal arrangements with the local NSP (Kimergård and McVeigh, 2014), 
however obtaining owner consent can be a barrier (Bates et al., 2014).  
Lastly, this study highlights the need for NSPs to appropriately address secondary 
distribution. Services, including pharmacy exchanges, should be willing and able to provide 
sufficient injecting equipment for additional onward distribution, alongside information in-line 
with current guidelines (NICE, 2014b). 
People who inject IPEDs are mostly a discrete population from those who inject 
psychoactive drugs; however there is an overlap between these two groups. People injecting 
both IPEDs and psychoactive drugs were found to be older, report higher uptake of 
interventions, riskier injecting practices and more often collected equipment for others. A 
variety of factors may influence this: being older they may have been injecting for longer and 
be more established in user networks, or they could be more comfortable attending NSPs 
due to greater exposure through psychoactive drug use, and therefore attend more often. 
However, the extent of secondary distribution was similar for people who had only injected 
IPEDs and those who had also injected psychoactive drugs. Compared to international 
studies among people who predominantly or exclusively inject psychoactive drugs, the 
proportion collecting for onward distribution in our study was lower (Bryant and Hopwood, 
2009; Newland et al., 2016a; Tyndall et al., 2002), however psychoactive injectors often 
distribute in smaller networks or to partners (Bryant and Hopwood, 2009). Newland et al., 
found a comparable proportion reporting large-scale distribution (16%) (Newland et al., 
2016a) to our study (13%).   
There are limitations to our study to consider. Firstly, we are unable to know whether the 
individuals collecting for multiple others are doing so on a rotational basis within their 
distribution network. Thus some of those being collected for may also use NSPs (Newland et 
al., 2016b). Additionally tertiary distribution, where clients may pass equipment onto an 
individual (potentially a training partner) who again distributes equipment to others, may be 
occurring and unaccounted for. We also have no information on those who only obtain 
needles from other sources, such as, through online purchases. Secondly, the data on NSP 
use relies on self-report and is therefore subject to recall bias. Despite the survey’s 
anonymity, participants may be reluctant to disclose the extent of their redistribution due to 
concerns over a reduction in provision. Due to using discrete answer categories, our 
estimates of onward distribution include ambiguity. Finally, as information on the size and 
nature of this population is currently limited, we are unable to assess the representativeness 
of the sample and the generalizability of these findings.  
 
5. Conclusion 
Secondary distribution of injecting equipment obtained from NSPs is common among those 
injecting IPEDs. The number of people for whom equipment was collected was greater than 
the number participating in our study. Our study suggests that many, possibly a majority, of 
those injecting IPEDs are not in direct contact with NSPs. Those who were also injecting 
psychoactive drugs more often collected equipment for others. NSPs should target those 
collecting for others as potential peer educators for cascading harm reduction messages and 
explore alternative platforms for communicating safer injecting practices among people who 
inject IPEDs. 
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Table 1: Characteristics of study participants by whether they attended a (NSP) and reported collecting equipment for others 
  
Attended an NSP; n (%) 
Among those attending NSP: 
Collected equipment for others; n (%) 
  
Yes  No p Yes  No p 
Total number of participants 
 
467 70 
 
157 310 
 Demographics   
Age 
< 25 years 97 (21%) 20 (29%) 
0.334 
30 (19%) 67 (22%) 
0.275 25-34 years 203 (44%) 28 (40%) 63 (40%) 140 (45%) 
>=35 years 167 (36%) 22 (31%) 64 (41%) 103 (33%) 
Gender Male 457 (98%) 69 (99%) 0.695 153 (97%) 304 (98%) 0.666 
Origin of birth UK born 447 (96%) 65 (93%) 0.289 151 (96%) 296 (95%) 0.726 
Ever imprisoned Yes 116 (25%) 14 (20%) 0.378 45 (29%) 71 (23%) 0.174 
Intervention uptake (ever reported)   
Hepatitis B vaccination (at least one dose) Yes 190 (41%) 23 (33%) 0.212 70 (45%) 120 (39%) 0.222 
Tested for hepatitis C  Yes 181 (39%) 20 (29%) 0.101 63 (40%) 118 (38%) 0.666 
Infection harms and risks (ever)         
Redness, tenderness and swelling at an injection site Yes 286 (61%) 24 (34%) <0.001 107 (68%) 179 (58%) 0.029 
Abscess, a sore, or an open wound at an injection site Yes 74 (16%) 6 (8.6%) 0.111 33 (21%) 41 (13%) 0.029 
Anti-HCV Positive 24 (5.1%) 1 (1.4%) 0.169 12 (7.6%) 12 (3.9%) 0.081 
Anti-HIV Positive 7 (1.5%) 0 (0%) 0.303 3 (1.9%) 4 (1.3%) 0.602 
Anti-HBc Positive 14 (3.0%) 1 (1.4%) 0.457 8 (5.1%) 6 (1.9%) 0.059 
Injecting behaviour   
IPED injected in preceding year 
Anabolic steroids 389 (94%) 45 (98%) 0.262 130 (93%) 259 (94%) 0.599 
Growth hormone 146 (35%) 14 (30%) 0.521 56 (40%) 90 (33%) 0.142 
Human chorionic 
gonadotropin 
113 (27%) 8 (17%) 0.15 33 (24%) 80 (29%) 0.232 
Melanotan 54 (13%) 3 (6.5%) 0.205 23 (16%) 31 (11%) 0.14 
Injected psychoactive substances 
Yes, ever 65 (14%) 6 (8.6%) 0.218 30 (19%) 35 (11%) 0.021 
Yes, in preceding year 29 (6.2%) 2 (2.9%) 0.262 17 (11%) 12 (3.9%) 0.011 
Ever re-used own needles Yes 78 (17%) 6 (8.6%) 0.081 33 (21%) 45 (15%) 0.075 
Ever used other people’s needles Yes 15 (3.2%) 0 (0%) 0.128 8 (5.1%) 7 (2.3%) 0.1 
Ever shared a vial Yes 56 (12%) 4 (5.7%) 0.12 29 (18%) 27 (9%) 0.002 
Table 2: Extent of onward distribution reported by those who collect injecting 
equipment for others 
Number of users who 
reported collecting for: 
n % 
Estimated onward distribution 
Low a Mid b High c 
1 other 85 55% 85 85 85 
2-9 others 42 27% 84 210 378 
10-19 others 7 4.6% 70 105 133 
20+ others 20 13% 400 600 1,000 
Total 154 100% 639 1,000 1,596 
a  calculated using bottom of the category ranges, i.e. 1, 2, 10, & 20  
b  calculated using mid-point of the category ranges i.e. 1, 5  & 15 with 30 used for 20+ category 
c  calculated using top of the category ranges, i.e. 1, 9 & 19, with 50 is used for the 20+ category 
 
 
